Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients | Zendy

Ryōji Kobayashi | Zendy; Daiki Hori | Zendy; Hirozumi Sano | Zendy; Daisuke Suzuki | Zendy; Kenji Kishimoto | Zendy; Kunihiko Kobayashi | Zendy

Open Access

Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients

Author(s) -

Ryōji Kobayashi,

Daiki Hori,

Hirozumi Sano,

Daisuke Suzuki,

Kenji Kishimoto,

Kunihiko Kobayashi

Publication year - 2017

Publication title -

journal of microbiology immunology and infection

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.223

H-Index - 57

eISSN - 1995-9133

pISSN - 1684-1182

DOI - 10.1016/j.jmii.2017.06.005

Subject(s) - medicine , piperacillin , tazobactam , meropenem , piperacillin/tazobactam , neutropenia , febrile neutropenia , surgery , antibiotics , chemotherapy , microbiology and biotechnology , biology , genetics , antibiotic resistance , bacteria , pseudomonas aeruginosa

Although survival of children with hematological diseases and cancer has increased dramatically, life-threatening complications due to bacterial infections occur in 5-10% of febrile episodes in pediatric cancer patients. A prospective randomized study was performed to clarify the usefulness of meropenem (MEPM) and piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG) as second-line therapy for pediatric patients with febrile neutropenia (FN).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research